- Home
- BIIB vs ODFL Comparison
BIIB vs ODFL Comparison
Compare BIIB & ODFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIIB | ODFL |
|---|---|---|
| Founded | 1978 | 1934 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 28.2B |
| IPO Year | 1991 | 1991 |
Fundamental Metrics
Financial Performance| Metric | BIIB | ODFL |
|---|---|---|
| Price | $173.85 | $156.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 19 |
| Target Price | ★ $177.40 | $161.78 |
| AVG Volume (30 Days) | 2.0M | ★ 2.6M |
| Earning Date | 10-30-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 0.70% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 10.97 | 4.97 |
| Revenue | ★ $10,065,900,000.00 | $5,574,922,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | $3.73 |
| P/E Ratio | ★ $15.86 | $32.10 |
| Revenue Growth | ★ 4.77 | N/A |
| 52 Week Low | $110.04 | $126.01 |
| 52 Week High | $185.17 | $209.61 |
Technical Indicators
Market Signals| Indicator | BIIB | ODFL |
|---|---|---|
| Relative Strength Index (RSI) | 55.20 | 63.26 |
| Support Level | $169.24 | $147.86 |
| Resistance Level | $180.79 | $163.19 |
| Average True Range (ATR) | 4.98 | 5.07 |
| MACD | -1.64 | 1.86 |
| Stochastic Oscillator | 35.73 | 75.46 |
Price Performance
Historical ComparisonAbout BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About ODFL Old Dominion Freight Line Inc.
Old Dominion Freight Line is the second-largest less-than-truckload carrier in the United States (following FedEx Freight), with more than 250 service centers and 11,000-plus tractors. It is one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns are head and shoulders above its peers. Strategic initiatives revolve around boosting network density through market share gains and maintaining industry-leading service (including ultralow cargo claims) via steadfast infrastructure investment.